… company was founded in 2012, our mission has been to help people living with rare diseases that currently have no treatment options. This remains an important focus of our company … Read more about our Founding story . Patient-focused drug development Patient-focused drug development In order to …
Find all relevant presentations and publications for each of our programs. From review papers to preclinical posters and clinical data presentations at medical conferences.
… ways, including via the Whistleblower Hotline which is operated by a third party SpeakUp and always available. The … confidential communication, and also allows for (optional) anonymous reporting. Report submitted to the … who will decide on further steps of investigation, as appropriate. Whistleblower Hotline reports may be made via …
… was diagnosed with a rare disease, he started ProQR to develop RNA therapies for rare diseases. Before founding … background in RNA modulation and orphan drug discovery and development and is currently in charge of our R&D. Gerard has … has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for …
… In cholestatic livers diseases, bile acids can’t flow properly from the liver to the gut. Excess bile acids … including the bile duct, can also become irritated and stop working as they should. As the disease progresses, the … diseases can affect individuals of all ages, yet treatment options are limited. AX-0810 targeting NTCP AX-0810 is an RNA …
… be themselves, feel comfortable in our workplace, and help develop our next generation of RNA medicines. Being yourself … join us at ProQR couldn’t be easier. If you are sending an open application or have found a vacancy that catches your … forms and, at your discretion, please include any optional information that will help us get to know you …
… sepofarsen captain. The work of her department, aimed at developing a novel drug for Leber congenital amaurosis 10 … in Venezuela and now heading ProQR’s LCA research and development team in Leiden (The Netherlands), has multiple reasons for being optimistic. Obviously, as a biotech scientist looking for a …
… cellular systems. Proficiency in Cell-type specific method development: Proven ability to develop and optimize methods using endosomal escape reagents (strongly …
… simulations to support go/no-go decisions, trial design optimization, and regulatory interactions. Skills and … are a true believer of the value of a workforce in which people from diverse backgrounds are encouraged to develop themselves, personally and professionally. We believe …
